

FASST

FOR A SYSTEMIC SCLEROSIS TREATMENT

Clinical Trial
Newsletter # 4
May 2016

Dear Colleagues,

Thank you for your continued enthusiasm for the FASST Trial!

We are very glad to share with you today the news of the publication in the **Annals of the Rheumatic Diseases** of the article: *Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis*. Please see below the information to access this article for free, thanks to the support of Inventiva.

We rely on you to keep up the good work with patients enrollment. The numbers are already very promising.

Please let us know if there is anything we can do to improve your experience as FASST investigators!

Sincerely,

Yannick Allanore
Paris Descartes University,
Paris


Chris Denton
Royal Free Hospital,
London

PATIENT ENROLLMENT IS ON THE RIGHT TRACK. PLEASE KEEP UP THE GOOD WORK!

- As of today, 19 patients have received study treatment and some for more than 24 weeks.
- All patients are monitored for Adverse Events, vital signs and laboratory parameters. No Serious Adverse Events have been reported.



KEEP GOING!



Country	SITES		PATIENTS	
	Selected	Active	Randomized	Screening in progress
France	6	4	7	
Germany	10	1	1	
Italy	11	3	5	
Netherlands	2			
Poland	10			
Spain	9	3	2	1
Switzerland	2	1	1	
United-Kingdom	3	1	3	1
Total	53	13	19	2

FASST Investigational sites as of May 16, 2016
Selected sites / active sites

IVA337 article in the Annals of the Rheumatic Diseases

The article « Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis », written by Prof. Yannick Allanore's team, has been published in the **Annals of the Rheumatic Diseases** (Online First, 9 March 2016).

This article reports a study of the antifibrotic effects of IVA337, using a bleomycin-induced mouse model of dermal fibrosis.

In conclusion, the findings of this study indicate that simultaneous activation of all three PPAR isoforms exerts a dampening effect on inflammation and fibrosis, making IVA337 a potentially effective therapeutic candidate in the

treatment of fibrotic diseases including SSC.

Thanks to the support of Inventiva, the article is available for free in Open Access.

[You can download it on the ARD website.
http://ard.bmj.com/
content/early/2016/04/22/
annrheumdis-2015-208029](http://ard.bmj.com/content/early/2016/04/22/annrheumdis-2015-208029)

Annals of the RHEUMATIC DISEASES The EULAR Journal



2nd Investigator Meeting in Warsaw

The FASST trial has now been extended to Poland and the Netherlands. Additional sites will also be implemented in Germany.

This Investigator meeting is planned in Warsaw, Poland, on May 18th, 2016. This meeting will be gathering a great majority of the Polish, German and Dutch FASST investigational sites and will be an opportunity to discuss IVA337 and the trial, review the protocol and exchange with fellow colleagues.

Any questions or requests ?



Please let us know if there is anything you need to facilitate the implementation of the FASST trial.

If you encounter any difficulties, we will be happy to take appropriate measures to help you.

The project team is here to help and support you in making this trial a success !


You can contact us by email:

mari-carmen.delatte@inventivapharma.com

OR

fasst_inventiva@margauxorange.com

Have you visited the FASST Trial website yet?



www.fassttrial.com



We have developed the FASST Trial website as a tool to answer any questions you might have about the study and give you access to all the useful documents, news and updates.

The **general part of the website** is accessible to all and can provide information for anyone who is interested in systemic sclerosis treatment and wants to learn about the trial.

The **Investigators section** is reserved for the confirmed Investigational Sites. You will need your site ID number and a password to access this section. These connection details have been sent to each Principal Investigator on March 15th. If you need to receive these again, please email your request to: fasst_inventiva@margauxorange.com

We are eager to make this website as useful as possible for you and **we would be happy to have your feedback**. Please tell us about the features you like and areas where we could improve. Tell us about content or services you would like to see and let us know if you could not find what you were looking for.